Select Publications

Albain K et al. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal, node-positive, ER-positive breast cancer (S8814,INT0100). San Antonio Breast Cancer Symposium 2007;Abstract 10.

Coombes RC et al. Survival and safety of exemestane versus tamoxifen after 2-3 years’ tamoxifen treatment (Intergroup Exemestane Study): A randomised controlled trial. Lancet 2007;369(9561):559-70. Abstract

Dowsett M et al. Risk of distant recurrence using Oncotype DX in postmenopausal primary breast cancer patients treated with anastrozole or tamoxifen: A TransATAC study. Presentation. San Antonio Breast Cancer Symposium 2008;Abstract 53.

Eiermann W et al. BCIRG 005 main efficacy analysis: A phase III randomized trial comparing docetaxel in combination with doxorubicin and cyclophosphamide (TAC) versus doxorubicin and cyclophosphamide followed by docetaxel (ACT) in women with Her-2/neu negative axillary lymph node positive early breast cancer. San Antonio Breast Cancer Symposium 2008;Abstract 77.

Ingle JN et al. Aromatase inhibitors versus tamoxifen as adjuvant therapy for postmenopausal women with estrogen receptor positive breast cancer: Meta-analyses of randomized trials of monotherapy and switching strategies. San Antonio Breast Cancer Symposium 2008;Abstract 12.

Jakesz R et al. Tamoxifen and anastrozole as a sequencing strategy in postmenopausal women with hormone-responsive early breast cancer: Updated data from the Austrian breast and colorectal cancer study group trial 8. San Antonio Breast Cancer Symposium 2008;Abstract 14.

Jones S et al. Docetaxel with cyclophosphamide is associated with an overall survival benefit compared with doxorubicin and cyclophosphamide: 7-year follow-up of US Oncology Research Trial 9735. J Clin Oncol 2009;27(8):1177-83. Abstract

Jones SE et al. Results of the first planned analysis of the TEAM (Tamoxifen Exemestane Adjuvant Multinational) prospective randomized phase III trial in hormone sensitive postmenopausal early breast cancer. San Antonio Breast Cancer Symposium 2008;Abstract 15.

Mouridsen HT et al. BIG 1-98: A randomized double-blind phase III study evaluating letrozole and tamoxifen given in sequence as adjuvant endocrine therapy for postmenopausal women with receptor-positive breast cancer. San Antonio Breast Cancer Symposium 2008;Abstract 13.

Swain SM et al. NSABP B-30: Definitive analysis of patient outcome from a randomized trial evaluating different schedules and combinations of adjuvant therapy containing doxorubicin, docetaxel and cyclophosphamide in women with operable, node-positive breast cancer. San Antonio Breast Cancer Symposium 2008;Abstract 75.

 

 

 

 

 

 

 

Home · Search

EDITOR
Neil Love, MD

INTERVIEWS

Edith A Perez, MD
- Select publications

Stephen E Jones, MD
- Select publications

Sandra M Swain, MD
- Select publications

Ian E Krop, MD, PhD
- Select publications

 

Breast Cancer Update:
A CME Audio Series and Activity

Faculty Disclosures

Editor's Office